Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
Pediatric Pulmonology · 2026-01 · 61 (1)
DOI: 10.1002/ppul.71461 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, online erschienen am 07.01.2026. Verfasst von Sara Kümmerli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quality of Life, Aminophenols, Quinolones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Switzerland, Fondation Respirer.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
CFTR modulators have revolutionized cystic fibrosis (CF) management by targeting the defective protein rather than its consequences. Their impact on quality of life (QoL) have been studied in numerous trials, but few data are available on QoL in patients receiving Elexacaftor‐Tezacaftor‐Ivacaftor (ETI), notably in children given its recent authorization for this age group. We aimed to assess the impact of ETI on children's QoL.
Methods
This prospective observational study included children with CF (6−17 years), assessing QoL using the CF Questionnaire Revised (CFQ‐R) before (baseline) and 3 months after (M3) starting ETI treatment for children and their caregivers.
Results
We included 23 children (median [range]) age 10.2 [6−17.2] years, 13 (57%) with homozygous F508del genotype. The total QoL score at baseline ([mean (SD)] children: 74.07 [10.86]; caregivers: 73.21 [10.38]) reflected severe disease impact, particularly regarding treatment burden in the children's perspective (63.28 [21.04]) and digestive domains in the caregivers' perspective (digestive symptoms: 66.67 [17.37]; eating disorder: 67.54 [32.14]; weight: 61.40 [33.82]). At M3, there was a significant increase in reported QoL ( p = 0.0001), particularly regarding physical domains. Emotional/social/school domains barely showed improvement. Although QoL mean scores were comparable between children and caregivers' groups, they were poorly correlated within the same family. Homozygous F508del genotype was associated with better QoL improvement at M3 compared to composite heterozygous genotypes ( p < 0.001).
Conclusion
ETI treatment has a significant impact on children's QoL, particularly in physical health domains. Other QoL domains that are not improved by ETI need to be addressed, in particular, psycho‐social components. Both children's and caregivers' perspectives must be considered for a holistic picture of children's QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland.
- Pediatric Pulmonology and Cystic Fibrosis Unit, University Hospital of Geneva, Geneva, Switzerland.
- Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Sara Kümmerli, Nicolas Regamey, Isabelle Rochat, Sylvain Blanchon
Förderung
- Cystic Fibrosis Switzerland
- Fondation Respirer
Zitieren
APA
Kümmerli, S., Elviro, C. F., Regamey, N., Mornand, A., Faouzi, M., Rochat, I., & Blanchon, S. (2026). Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis. Pediatric Pulmonology, 61(1). https://doi.org/10.1002/ppul.71461
Vancouver
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, et al. Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis. Pediatric Pulmonology. 2026;61(1). doi:10.1002/ppul.71461
BibTeX
@article{Kmmerli2026,
author = {Kümmerli, Sara and Elviro, Clara Fernandez and Regamey, Nicolas and Mornand, Anne and Faouzi, Mohamed and Rochat, Isabelle and Blanchon, Sylvain},
title = {Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {1},
doi = {10.1002/ppul.71461}
}
EUVIMED